1. Home
  2. DOMH vs KZIA Comparison

DOMH vs KZIA Comparison

Compare DOMH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • KZIA
  • Stock Information
  • Founded
  • DOMH 1967
  • KZIA 1994
  • Country
  • DOMH United States
  • KZIA Australia
  • Employees
  • DOMH N/A
  • KZIA N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • KZIA Health Care
  • Exchange
  • DOMH Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • DOMH 8.8M
  • KZIA 7.8M
  • IPO Year
  • DOMH N/A
  • KZIA 1999
  • Fundamental
  • Price
  • DOMH $3.02
  • KZIA $1.29
  • Analyst Decision
  • DOMH
  • KZIA Strong Buy
  • Analyst Count
  • DOMH 0
  • KZIA 2
  • Target Price
  • DOMH N/A
  • KZIA $11.50
  • AVG Volume (30 Days)
  • DOMH 427.5K
  • KZIA 5.5M
  • Earning Date
  • DOMH 03-31-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • DOMH N/A
  • KZIA N/A
  • EPS Growth
  • DOMH N/A
  • KZIA N/A
  • EPS
  • DOMH N/A
  • KZIA N/A
  • Revenue
  • DOMH $12,589,000.00
  • KZIA $1,655,324.00
  • Revenue This Year
  • DOMH N/A
  • KZIA $806.89
  • Revenue Next Year
  • DOMH N/A
  • KZIA N/A
  • P/E Ratio
  • DOMH N/A
  • KZIA N/A
  • Revenue Growth
  • DOMH 1117.50
  • KZIA 248000.00
  • 52 Week Low
  • DOMH $0.83
  • KZIA $1.25
  • 52 Week High
  • DOMH $4.35
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 65.22
  • KZIA 39.50
  • Support Level
  • DOMH $2.86
  • KZIA $1.31
  • Resistance Level
  • DOMH $4.35
  • KZIA $2.64
  • Average True Range (ATR)
  • DOMH 0.52
  • KZIA 0.24
  • MACD
  • DOMH 0.14
  • KZIA 0.09
  • Stochastic Oscillator
  • DOMH 53.19
  • KZIA 14.29

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: